- Report
- May 2024
- 327 Pages
Global
From €3528EUR$4,000USD£3,100GBP
- Report
- January 2024
- 200 Pages
Global
From €3661EUR$4,150USD£3,216GBP
- Report
- August 2023
- 145 Pages
Global
From €2779EUR$3,150USD£2,441GBP
- Report
- March 2023
- 209 Pages
Global
From €3925EUR$4,450USD£3,448GBP
- Report
- October 2022
- 232 Pages
Global
From €3175EUR$3,600USD£2,790GBP
- Report
- October 2022
- 91 Pages
Europe
From €1323EUR$1,500USD£1,162GBP
- Report
- October 2022
- 91 Pages
Middle East, Africa
From €1323EUR$1,500USD£1,162GBP
- Report
- June 2023
- 89 Pages
Global
From €2205EUR$2,500USD£1,937GBP
- Report
- June 2021
- 102 Pages
Global
€19406EUR$22,000USD£17,048GBP
- Report
- February 2024
- 112 Pages
Global
From €3500EUR$4,251USD£3,182GBP
- Report
- November 2025
- 132 Pages
Global
From €838EUR$950USD£736GBP
- Report
- November 2025
- 132 Pages
Global
From €838EUR$950USD£736GBP
- Book
- May 2019
North America

Von Willebrand Disease (VWD) is a rare inherited bleeding disorder caused by a deficiency or defect in the von Willebrand factor (VWF), a protein that helps the blood to clot. It is the most common inherited bleeding disorder, affecting both males and females. Symptoms of VWD can range from mild to severe, and include prolonged bleeding from cuts, nosebleeds, and heavy menstrual bleeding. Treatment for VWD typically involves the use of desmopressin, a synthetic form of the hormone vasopressin, and/or replacement therapy with VWF concentrates.
The VWD market is a subset of the larger hematology market, which includes treatments for a variety of blood-related disorders. The VWD market is expected to grow due to increasing awareness of the disorder, as well as the development of new treatments.
Companies in the VWD market include Shire, CSL Behring, Octapharma, Grifols, and Kedrion. Show Less Read more